Explore our validated phytochemical services, analytical testing methods, and contract manufacturing solutions tailored for high-potency formulations across pharmaceutical, nutraceutical, and cosmeceutical sectors.
MedGence (Yineng Pharma) integrates contract research (CRO) and custom development and manufacturing (CDMO) under one validated roof, transforming unstandardized botanical biomass into reproducible, pharmacologically quantified extracted compounds.
In the global procurement of natural medicine and high-purity botanical actives, traditional wildcrafting and rudimentary extraction processes no longer satisfy international regulatory authorities. Natural variations in phytochemical potency caused by geographic soil composition, altitude, diurnal temperature fluctuations, and harvest windows have historically compromised batch consistency. MedGence solves this systemic vulnerability by pairing advanced chemotaxonomic identification with modern separation engineering.
Over 14+ years of focused botanical R&D, our multidisciplinary team of over 300 research scientists and regulatory pharmacologists has completed comprehensive modern medical evaluations of 83 classic Traditional Chinese Medicine (TCM) formulations, engineered 22 innovative natural pharmaceutical candidates, secured 56 hospital preparation registrations, and drafted monograph-grade quality standards for nearly 400 single-herb medicines. Our integrated CRO-to-CDMO pipeline eliminates the operational handover risks that conventionally exist between exploratory university laboratories and high-tonnage contract manufacturers.
From green extraction thermodynamics to targeted crystallization and nano-emulsion bio-enhancement, our research laboratories drive innovation across every tier of botanical substance isolation.
Employing subcritical and supercritical carbon dioxide with customizable ethanol co-solvents to extract lipophilic bio-actives and volatile terpenoids without thermal degradation or toxic halogenated solvent residues.
Targeted separation of specialized polyphenols, saponins, and alkaloids utilizing tailored macroporous non-ionic adsorptive and ion-exchange polymer resins, achieving purity concentrations upwards of 98.5% with high batch yield recovery.
High-vacuum, ultra-low exposure time thermal fractionation applied to heat-sensitive botanical essential oils and fatty acid derivatives, isolating individual high-value terpenes while purging volatile off-notes and coloring agents.
Transforming hygroscopic botanical extracts into free-flowing, non-caking, and directly compressible powders via cyclodextrin complexation, liposomal encapsulation, and closed-circuit inert nitrogen spray drying towers.
Overcoming the historical low intestinal permeability and rapid metabolic clearance of phytochemicals through self-microemulsifying drug delivery systems (SMEDDS), nanoparticle dispersion, and phytosome phospholipid conjugation.
Deploying quantitative structure-activity relationship (QSAR) algorithms and in silico molecular docking models against target biological receptors, expediting discovery timelines from traditional months to targeted days.
We supply verified extracted compounds engineered to satisfy the rigorous technical, legal, and consumer requirements of differentiated market segments.
Turnkey active ingredients featuring validated sensory neutralization, 100% water solubility for functional beverages, verified shelf-life stability profiles, and clean-label non-GMO status substantiated by comprehensive third-party testing.
Investigational botanical drug active pharmaceutical ingredients (APIs) supported by complete Chemistry, Manufacturing, and Controls (CMC) dossiers, GLP-compliant preclinical toxicology packages, and FDA Phase I–IV clinical designs.
Cell-tested botanical fractions providing clinically demonstrated tyrosinase inhibition, collagen synthesis stimulation, anti-inflammatory cytokine downregulation, and certified zero-irritation dermatological tolerability.
Combining agricultural Good Agricultural and Collection Practices (GACP) with continuous smart factory automation to deliver unmatched cost economies, zero inventory surprises, and multi-ton delivery guarantees.
Supply chain disruption in natural medicine typically stems from fragmented sourcing networks, uncontrolled seasonal shortages, and variable extraction yields. MedGence's manufacturing infrastructure in Hunan, China operates on an Industry 4.0 paradigm, combining directly managed agricultural provenance with continuous automated extraction lines capable of processing hundreds of metric tons of raw herbals each quarter.
Our centralized manufacturing ecosystem integrates DCS (Distributed Control Systems) and SCADA automation across solvent recovery, concentration evaporators, column loading, and drying parameters. This continuous digital process monitoring minimizes human intervention, eliminates batch cross-contamination, and achieves a solvent recovery rate exceeding 98.5%—driving production overhead downwards and passing significant margin savings to our global brand partners.
Institutional buyers require documented supply chain transparency, non-disclosure confidentiality, and unassailable analytical integrity to shield their global brands against liability.
Custom formulations, unique solvent extraction ratios, and novel therapeutic indications are governed under binding bilateral Non-Disclosure Agreements (NDAs). Proprietary data is segregated in encrypted internal systems.
Every commercial shipment is accompanied by a full Certificate of Analysis (COA) containing HPLC/GC assay percentages, HPTLC identification plates, heavy metal ICP-MS quantification, and complete microbial colony counts.
Full chain-of-custody documentation from raw herb harvest lots, transport waybills, extraction logbooks, and sterilization records to warehouse quarantine releases, satisfying modern supply-chain audits.
Overcoming regulatory hurdles across key target territories with comprehensive Chemistry, Manufacturing, and Controls (CMC) packages and pre-cleared dossier documentation.
Providing New Dietary Ingredient (NDI) notifications, Generally Recognized as Safe (GRAS) toxicological dossiers, and 21 CFR 111 cGMP compliance validation for North American brand owners and private labels.
Assisting clients with European Food Safety Authority (EFSA) Novel Food applications, traditional herbal medicinal product registrations (THMPD), and non-irradiation / non-ETO sterilization certifications.
Full registration support for China National Medical Products Administration (NMPA) health foods (Blue Hat certification) and Health Canada Natural Health Product (NPN) licensing dossiers.
Clear, direct answers regarding testing protocols, contract development timelines, minimum order quantities (MOQ), and intellectual property protection.
Ready to accelerate your botanical formulation pipeline? Select from our specialized contract study packages, testing capabilities, and commercial extracted compound supplies below.
Partner with MedGence (Yineng Pharma) to eliminate sourcing variability and regulatory friction. Direct technical inquiries to our scientific project team for feasibility reviews and customized pricing.
